Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2017
At a glance
- Drugs BAL 101553 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 14 Aug 2017 Status changed from planning to recruiting.
- 10 Aug 2017 According to a Basilea Pharmaceutica media release, this trial is expected to begin in the fourth quarter of this year.
- 15 Jun 2017 New trial record